Authors:
MORRILL JS
BUCSELA EJ
PASKO VP
BERG SL
HEAVNER MJ
MOUDRY DR
BENESCH WM
WESCOTT EM
SENTMAN DD
Citation: Js. Morrill et al., TIME-RESOLVED N-2 TRIPLET-STATE VIBRATIONAL POPULATIONS AND EMISSIONSASSOCIATED WITH RED SPRITES, Journal of atmospheric and solar-terrestrial physics, 60(7-9), 1998, pp. 811-829
Authors:
BLANEY SM
NEEDLE MN
GILLESPIE A
SATO JK
REAMAN GH
BERG SL
ADAMSON PC
KRAILO MD
BLEYER WA
POPLACK DG
BALIS FM
Citation: Sm. Blaney et al., PHASE-II TRIAL OF TOPOTECAN ADMINISTERED AS A 72-HOUR CONTINUOUS-INFUSION IN CHILDREN WITH REFRACTORY SOLID TUMORS - A COLLABORATIVE PEDIATRIC BRANCH, NATIONAL-CANCER-INSTITUTE, AND CHILDRENS CANCER GROUP-STUDY, Clinical cancer research, 4(2), 1998, pp. 357-360
Authors:
BLANEY SM
NEEDLE MN
GILLESPIE A
SATO JK
REAMAN GH
BERG SL
ADAMSON PC
KRAILO MD
BLEYER WA
POPLACK DG
BALIS FM
Citation: Sm. Blaney et al., PHASE-II TRIAL OF TOPOTECAN ADMINISTERED AS A 72-HOUR CONTINUOUS-INFUSION IN CHILDREN WITH REFRACTORY SOLID TUMORS - A COLLABORATIVE PEDIATRIC BRANCH, NATIONAL-CANCER-INSTITUTE, AND CHILDRENS CANCER GROUP-STUDY, Clinical cancer research, 4(2), 1998, pp. 357-360
Authors:
BERG SL
MURRY DJ
MCCULLY CL
GODWIN K
BALIS FM
Citation: Sl. Berg et al., PHARMACOKINETICS OF O-6-BENZYLGUANINE AND ITS ACTIVE METABOLITE 8-OXO-O-6-BENZYLGUANINE IN PLASMA AND CEREBROSPINAL-FLUID AFTER INTRATHECALADMINISTRATION OF O-6-BENZYLGUANINE IN THE NONHUMAN PRIMATE, Clinical cancer research, 4(11), 1998, pp. 2891-2894
Authors:
BERG SL
BLANEY SM
ADAMSON PC
OBRIEN M
POPLACK DG
ARNDT C
BLATT J
BALIS FM
Citation: Sl. Berg et al., PHASE-I TRIAL AND PHARMACOKINETIC STUDY OF PYRAZOLOACRIDINE IN CHILDREN AND YOUNG-ADULTS WITH REFRACTORY CANCERS, Journal of clinical oncology, 16(1), 1998, pp. 181-186
Authors:
BLANEY SM
SEIBEL NL
OBRIEN M
REAMAN GH
BERG SL
ADAMSON PC
POPLACK DG
KRAILO MD
MOSHER R
BALIS FM
Citation: Sm. Blaney et al., PHASE-I TRIAL OF DOCETAXEL ADMINISTERED AS A 1-HOUR INFUSION IN CHILDREN WITH REFRACTORY SOLID TUMORS - A COLLABORATIVE PEDIATRIC BRANCH, NATIONAL-CANCER-INSTITUTE AND CHILDRENS CANCER GROUP TRIAL, Journal of clinical oncology, 15(4), 1997, pp. 1538-1543
Authors:
ADAMSON PC
REAMAN G
FINKLESTEIN JZ
FEUSNER J
BERG SL
BLANEY SM
OBRIEN M
MURPHY RF
BALIS FM
Citation: Pc. Adamson et al., PHASE-I TRIAL AND PHARMACOKINETIC STUDY OF ALL-TRANS-RETINOIC ACID ADMINISTERED ON AN INTERMITTENT SCHEDULE IN COMBINATION WITH INTERFERON-ALPHA-2A IN PEDIATRIC-PATIENTS WITH REFRACTORY CANCER, Journal of clinical oncology, 15(11), 1997, pp. 3330-3337
Authors:
TOLCHER AW
COWAN KH
SOLOMON D
OGNIBENE F
GOLDSPIEL B
CHANG R
NOONE MH
DENICOFF AM
BARNES CS
GOSSARD MR
FETSCH PA
BERG SL
BALIS FM
VENZON DJ
OSHAUGHNESSY JA
Citation: Aw. Tolcher et al., PHASE-I CROSSOVER STUDY OF PACLITAXEL WITH R-VERAPAMIL IN PATIENTS WITH METASTATIC BREAST-CANCER, Journal of clinical oncology, 14(4), 1996, pp. 1173-1184
Authors:
WEXLER LH
ANDRICH MP
VENZON D
BERG SL
WEAVERMCCLURE L
CHEN CC
DILSIZIAN V
AVILA N
JAROSINSKI P
BALIS FM
POPLACK DG
HOROWITZ ME
Citation: Lh. Wexler et al., RANDOMIZED TRIAL OF THE CARDIOPROTECTIVE AGENT ICRF-187 IN PEDIATRIC SARCOMA PATIENTS TREATED WITH DOXORUBICIN, Journal of clinical oncology, 14(2), 1996, pp. 362-372
Authors:
BLANEY SM
PHILLIPS PC
PACKER RJ
HEIDEMAN RL
BERG SL
ADAMSON PC
ALLEN JC
SALLAN SE
JAKACKI RL
LANGE BJ
REAMAN GH
HOROWITZ ME
POPLACK DG
BALIS FM
Citation: Sm. Blaney et al., PHASE-II EVALUATION OF TOPOTECAN FOR PEDIATRIC CENTRAL-NERVOUS-SYSTEMTUMORS, Cancer, 78(3), 1996, pp. 527-531
Authors:
GREM JL
POLITI PM
BERG SL
BENCHEKROUN NM
PATEL M
BALIS FM
SINHA BK
DAHUT W
ALLEGRA CJ
Citation: Jl. Grem et al., CYTOTOXICITY AND DNA-DAMAGE ASSOCIATED WITH PYRAZOLOACRIDINE IN MCF-7BREAST-CANCER CELLS, Biochemical pharmacology, 51(12), 1996, pp. 1649-1659
Authors:
BERG SL
TOLCHER A
OSHAUGHNESSY JA
DENICOFF AM
NOONE M
OGNIBENE FP
COWAN KH
BALIS FM
Citation: Sl. Berg et al., EFFECT OF R-VERAPAMIL ON THE PHARMACOKINETICS OF PACLITAXEL IN WOMEN WITH BREAST-CANCER, Journal of clinical oncology, 13(8), 1995, pp. 2039-2042
Authors:
BERG SL
GERSON SL
GODWIN K
COLE DE
LIU L
BALIS FM
Citation: Sl. Berg et al., PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF O-6-BENZYLGUANINE AND TIME-COURSE OF PERIPHERAL-BLOOD MONONUCLEAR CELL O-6-METHYLGUANINE-DNA METHYLTRANSFERASE INHIBITION IN THE NONHUMAN PRIMATE, Cancer research, 55(20), 1995, pp. 4606-4610
Authors:
ADAMSON PC
BALLS FM
BELASCO JE
LANGE B
BERG SL
BLANEY SM
CRAIG C
POPLACK DG
Citation: Pc. Adamson et al., A PHASE-I TRIAL OF AMIFOSTINE (WR-2721) AND MELPHALAN IN CHILDREN WITH REFRACTORY CANCER, Cancer research, 55(18), 1995, pp. 4069-4072
Authors:
BERG SL
COWAN KH
BALIS FM
FISHERMAN JS
DENICOFF AM
HILLIG M
POPLACK DG
OSHAUGHNESSY JA
Citation: Sl. Berg et al., PHARMACOKINETICS OF TAXOL AND DOXORUBICIN ADMINISTERED ALONE AND IN COMBINATION BY CONTINUOUS 72-HOUR INFUSION, Journal of the National Cancer Institute, 86(2), 1994, pp. 143-145
Authors:
WILSON WH
BERG SL
BRYANT G
WITTES RE
BATES S
FOJO A
STEINBERG SM
GOLDSPIEL BR
HERDT J
OSHAUGHNESSY J
BALIS FM
CHABNER BA
Citation: Wh. Wilson et al., PACLITAXEL IN DOXORUBICIN-REFRACTORY OR MITOXANTRONE-REFRACTORY BREAST-CANCER - A PHASE I II TRIAL OF 96-HOUR INFUSION/, Journal of clinical oncology, 12(8), 1994, pp. 1621-1629
Authors:
SAVARESE DMF
DENICOFF AM
BERG SL
HILLIG M
BAKER SP
OSHAUGHNESSY JA
CHOW C
OTTERSON GA
BALIS FM
POPLACK DG
COWAN KH
Citation: Dmf. Savarese et al., PHASE-I STUDY OF HIGH-DOSE PIROXANTRONE WITH GRANULOCYTE-COLONY-STIMULATING FACTOR, Journal of clinical oncology, 11(9), 1993, pp. 1795-1803
Citation: Sl. Berg et al., PHARMACOKINETICS OF PEG-L-ASPARAGINASE AND PLASMA AND CEREBROSPINAL-FLUID L-ASPARAGINE CONCENTRATIONS IN THE RHESUS-MONKEY, Cancer chemotherapy and pharmacology, 32(4), 1993, pp. 310-314
Citation: Sl. Berg et al., PHARMACOKINETICS, CEREBROSPINAL-FLUID PENETRATION, AND METABOLISM OF PIROXANTRONE IN THE RHESUS-MONKEY, Investigational new drugs, 11(4), 1993, pp. 255-261
Authors:
BERG SL
SAVARESE DMF
BALIS FM
DENICOFF AM
HILLIG M
OSHAUGHNESSY JA
POPLACK DG
COWAN KH
Citation: Sl. Berg et al., PHARMACOKINETICS OF PIROXANTRONE IN A PHASE-I TRIAL OF PIROXANTRONE AND GRANULOCYTE-COLONY-STIMULATING FACTOR, Cancer research, 53(11), 1993, pp. 2587-2590